Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 31, Number 6—June 2025
Dispatch
Cadaveric Human Growth Hormone–Associated Creutzfeldt-Jakob Disease with Long Latency Period, United States
Figure 2

Figure 2. Comparison of latency estimates among US cases in a study of chGH-associated CJD with long latency period, United States. The patient in this report (current CJD case) was treated with chGH for 9.3 years starting in late 1971 at 7 years of age, and neurologic symptoms developed when she was 58 years of age. We used data from all 36 US cases of chGH-associated CJD to compare estimates of CJD latency periods via 4 methods: first dose of chGH to symptom onset (red), midpoint of chGH treatment to symptom onset (green), last dose of chGH to symptom (blue), and midpoint of pre-1978 chGH to symptom onset (purple). Using those 4 methods, we believe the last (purple box plot) to be the most accurate, giving a best estimate of 48.3 years for our patient’s latency period. Black dots indicate other CJD cases, box top and bottoms indicate 25th and 75th percentiles, horizontal lines inside boxes indicate medians, and whiskers extend to the furthest observed points within 1.5 times the interquartile range from the 25th and 75th percentiles. chGH, cadaveric human growth hormone; CJD, Creutzfeldt-Jakob disease.